SCHEMBL3984192

SCHEMBL3984192

Nc1c(Cl)cnn(-c2ccccc2)c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.70
SMN1; SMN2 Q16637 5/20 0.70
NPC1 O15118 5/20 0.70
HTT P42858 4/20 0.70
ALDH1A1 P00352 4/20 0.70
MAPT P10636 3/20 0.70
PAX8 Q06710 3/20 0.70
MITF O75030 1/20 0.70
S1PR4 O95977 1/20 0.70
THRB P10828 1/20 0.70
XBP1 P17861 1/20 0.70
S1PR1 P21453 1/20 0.70
GAA P10253 1/20 0.62
NPBWR1 P48145 5/20 0.54
NPSR1 Q6W5P4 4/20 0.54
CYP1A2 P05177 3/20 0.54
CYP2C9 P11712 3/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2C19 P33261 2/20 0.54
MCHR1 Q99705 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1461789 0.82 RAB9A (1.00) RAB9ASMN1; SMN2NPC1HTTALDH1A1
SCHEMBL13967303 0.80 NPBWR1 (0.58) RAB9ASMN1; SMN2NPC1HTTALDH1A1
Pyrazon SCHEMBL1858918 0.79 RAB9A (0.70) RAB9ASMN1; SMN2NPC1HTTALDH1A1
Pyrazon SCHEMBL53824 0.79 RAB9A (0.70) RAB9ASMN1; SMN2NPC1HTTALDH1A1
SCHEMBL13219331 0.76 RAB9A (0.64) RAB9ASMN1; SMN2NPC1HTTALDH1A1
SCHEMBL4167058 0.76 RAB9A (0.53) RAB9ASMN1; SMN2NPC1HTTALDH1A1
Pyrazon SCHEMBL27859399 0.74 RAB9A (0.62) RAB9ASMN1; SMN2NPC1HTTALDH1A1
Pyrazon SCHEMBL16899678 0.74 RAB9A (0.62) RAB9ASMN1; SMN2NPC1HTTALDH1A1
SCHEMBL4172546 0.74 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2NPC1HTTALDH1A1
SCHEMBL13942534 0.73 NPC1 (0.70) RAB9ASMN1; SMN2NPC1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0413244-A2 Process for separation and recycling of by-products from the wastewater of the synthesis of 5-amino-4-chloro-2-phenyl-3(2H)-pyridazinone BASF Aktiengesellschaft (DE) 1991-02-20 EP claimed
US-4454318-A USING HYDROXY CONTAINING CATALYSTS BASF AKTIENGESELLSCHAFT (DE) 1984-06-12 US claimed
EP-0028359-B1 METHOD FOR PRODUCING 4-CHLORO-5-AMINO-2-PHENYL-3(2H)-PYRIDAZINONE FROM 4,5-DICHLORO-2-PHENYL-3(2H)-PYRIDAZINONE AND AMMONIA BASF Aktiengesellschaft (DE) 1984-04-11 EP claimed
US-4286092-A ACIDIFICATION OF AN ISOMERIC MIXTURE BY A MINERAL ACID TO DISSOLVE THE 4-AMINO ISOMER AND TO FORM A SUSPENSION OXON ITALIA S.P.A. (IT) 1981-08-25 US claimed
WO-1981001288-A1 METHOD FOR PRODUCING 4-CHLORO-5-AMINO-2-PHENYL-3(2H)-PYRIDAZINONE FROM 4,5-DICHLORO-2-PHENYL-3(2H)-PYRIDAZINONE AND AMMONIA KOEGE KEMISK VAERK (DK) 1981-05-14 WO claimed
EP-0028359-A1 Method for producing 4-chloro-5-amino-2-phenyl-3(2H)-pyridazinone from 4,5-dichloro-2-phenyl-3(2H)-pyridazinone and ammonia BASF Aktiengesellschaft (DE) 1981-05-13 EP claimed
US-4267323-A DIAZOTIZATION AND CYCLIZATION OF 5-CHLORO-4-AMINO-2-PHENYL-3/2H/-PYRIDAZINONE; AGRICULTURE; DYEING; DRUGS OXON ITALIA S.P.A. (IT) 1981-05-12 US claimed
US-4237287-A DIAZOTIZATION WITH SODIUM NITRITE AND CHLORINATION WITH THIONYL CHLORIDE OXON ITALIA S.P.A. (IT) 1980-12-02 US claimed
EP-1165520-B1 METHOD FOR PRODUCING 4-AMINO-5-CHLORO-1-PHENYL PYRIDAZINONE BASF SE (DE) 2009-05-20 EP disclosed
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-01-08 US disclosed
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2007-02-08 US disclosed
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2007-02-08 US disclosed
US-4267323-A DIAZOTIZATION AND CYCLIZATION OF 5-CHLORO-4-AMINO-2-PHENYL-3/2H/-PYRIDAZINONE; AGRICULTURE; DYEING; DRUGS OXON ITALIA S.P.A. (IT) 1981-05-12 US disclosed
EP-0026847-A1 Process for preparing 4-amino-5-chloro-1-phenylpyridazone-(6) BASF Aktiengesellschaft (DE) 1981-04-15 EP disclosed
US-4237287-A DIAZOTIZATION WITH SODIUM NITRITE AND CHLORINATION WITH THIONYL CHLORIDE OXON ITALIA S.P.A. (IT) 1980-12-02 US disclosed
US-4237287-A DIAZOTIZATION WITH SODIUM NITRITE AND CHLORINATION WITH THIONYL CHLORIDE OXON ITALIA S.P.A. (IT) 1980-12-02 US disclosed
US-4237287-A DIAZOTIZATION WITH SODIUM NITRITE AND CHLORINATION WITH THIONYL CHLORIDE OXON ITALIA S.P.A. (IT) 1980-12-02 US disclosed
US-3983168-A HERBICIDES MOBIL OIL CORPORATION (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032496-A1 Compounds for the Treatment of Neurodegeneration and Stroke PARP1, PARP12, PARP11 RAB9A 2534/4885SMN1; SMN2 89/4885NPC1 996/4885
US-20090012088-A1 Compounds for the Treatment of Neurodegeneration and Stroke PARP1, PARP12, PARP11 RAB9A 2534/4885SMN1; SMN2 89/4885NPC1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.